Sally Clive Research Group

Colorectal cancer and Cancers of Unknown Primary

S.Clive
Dr Sally Clive - Consultant and honorary senior lecturer in medical oncology

Research in a Nutshell

Dr Clive works as a consultant in medical oncology in the Edinburgh Cancer Centre and in NHS Fife, specialising in the medical management of colorectal cancer, cancers of unknown primary (CUP) and clinical trials. She also specialises in cancer medicine governance and national health technology appraisal of new medicines.

Sally has been chief investigator, principal investigator and co-investigator on numerous clinical trials over her career and works closely with medical colleagues in Edinburgh Cancer Research and NHS Fife, their clinical trials teams and the ECMC to deliver high quality trials with robust data and specimen collection. She has collaborated with colleagues across the UK and beyond on multicentre clinical trials (phase I-IV) with the overarching desire to make meaningful improvement to patient outcomes. Sally’s research interests focus specifically on improving pathways and outcomes and for patients with colorectal cancer and cancers of unknown primary.  

Sally’s work has been supported since 2012 by a NRS Career Researcher Award.

S.Clive group

People

  
Dr Sally Clive

Consultant Medical Oncologist and Honorary Senior Lecturer in Medical Oncology
Dr Stefan Symenoides Clinical lead in early phase clinical trials
Dr Ewan Brown Co-investigator in colorectal clinical trials
Dr Lesley Dawson Co-investigator in colorectal clinical trials
Dr Phil Yan Co-investigator in colorectal clinical trials
Dr Archie McNair Co-investigator in colorectal clinical trials
Dr Faye Robertson Co-investigator in colorectal clinical trials
Dr Colin Barrie Co-investigator in cancers of unknown primary
Dr Mark Stares Co-investigator in cancers of unknown primary
Mr Jim McPherson Lead data manager
Ms Heather McVicars Clinical research nurse manager

Contact

sally.clive@nhs.scot

Publications

  • Biomarkers of systemic inflammation provide additional prognostic stratification in cancers of unknown primary. Harvey S; Stares M, Scott J-A; Thottiyil, Tharun; Conway A-M, Haigh R,  Brown J, Knowles G, Dasgupta S, Shiu K-K, Mitchell C, Barrie C, Cook N, Clive S. Cancer Medicine, Feb 2024. http://doi.org/10.1002/cam4.6988
  • Characterisation and outcomes of patients referred to a regional Cancer of Unknown Primary Team: a 10-year analysis. Stares M, Purshouse K, Knowles G, Haigh R, Irvine J, Gatenby A, Patton R, McGinty J, Christie A, MacLennan M, Barrie C, Clive S.  British Journal Cancer, Sept 2021. 10.1038/s41416-021-01544-1
  • Efficacy of reduced intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastro-oesophageal cancer. The GO2 randomised clinical trial. Hall P, Swinson D, Cairns D, Clive S et al. JAMA Oncol. Published online May 13, 2021. https://doi.org/10.1001/jamaoncol.2021.0848
  • Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Bridgewater JA, Pugh S, Maishman T, Clive S et al. The Lancet Oncology 21 (3); 398-411, 2020. DOI: https://doi.org/10.1016/S1470-2045(19)30798-3
  • A biobank analysis of prognostic biomarkers of the systemic inflammatory response in patients with cancer of unknown primary; routine clinical tests predict outcome. Patton R, Stares M, Knowles G, Haigh R, Barrie C, Dobbs L, Laird B, Clive S. Eur J Cancer (2020); 139: 1-9. DOI: https://doi.org/10.1016/j.ejca.2020.07.036
  • Designing and evaluating dose-escalation studies made easy: the MoDEsT web app. Pallmann P, Wan F, Mander A, Wheeler G, Yap C, Clive S, Hampson L, Jaki T.  Clinical Trials (2019). DOI: 10.1177/1740774519890146
  • Vertebral fractures in patients treated with FOLFIRI-Cetuximab at the Edinburgh Cancer Centre. Swan A, Clive S, Dawson L, McGowan D, McLean C, Philips H, Sakala M, Zahra M, Brown E. British Journal of Cancer (2018); meeting supplement
  • A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. Woodcock VK, Clive S, Wilson RH, Coyle VM, Stratford MRL, Folkes LK, Eastell R, Barton C, Jones P, Kazmi-Stokes S, Turner H, Halford S, Harris AL, Middleton MR. British Journal Cancer (2018); 118, 770–776 | doi: 10.1038/bjc.2017.484
  • Embracing model based designs for dose finding studies. Love S, Brown S, Weir C,  Harbron C, Yap C, Gaschler-Markefski B, Matcham J, Caffery L, McKevitt C, Clive S, Craddock C, Spicer J, Cornelius V.  British Journal of Cancer (2017); 1–8 | doi: 10.1038/bjc.2017.186
  • Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunological and Clinical Outcomes and Survival. Cazaly A, Mander A, Chudley L, McCann K, Stasakova J, Thirdborough S, King A, Lloyd-Evans P, Buxton E, Edwards C, Bateman A, O’Callaghan A, Clive S, Anthoney DA, Jodrell D, Weinschenk T, Simon P, Sahin U, Thomas G, Stevenson FK, Ottensmeier CH. Clin Cancer Res. (2016) Oct 1; 22(19): 4827–4836. doi:  10.1158/1078-0432.CCR-15-2507
  • A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors. Ridoux L, Sémiond DR, Vincent C, Fontaine H, Mauriac C, Sanderink GJ, Oprea C, Kelly L, Clive S. Anti-Cancer Drugs (2015), 26:350–358
  • A Phase I, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Oral Panobinostat in Patients with Advanced Solid Tumors and Various Degrees of Hepatic Function.  Slingerland M, Hess D, Clive S, Sharma S, Sandstrom P, Loman N, Porro MG, Waldron E, Mu S, Valera S, Gelderblom H. Cancer Chemotherapy Pharmacology (2014); 74 (5): 1089-98
  • A phase 1/2, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.  Angevin E, Tabernero J, Elez ME, Cohen SJ, Bahleda R, Van Laethem JL, Ottensmeier CH, Lopez-Martin JA, Clive S et al. Clin Cancer Res (2014). Doi: http://clincancerres.aacrjournals.org/content/early/2014/02/21/1078-0432.CCR-13-2200.long
  • Development and implementation of a service of patients with cancer of unknown primary. Knowles G, Christie A, Bedi C, Dawson L, Mackean M, Wall L, Brown E, Clive S. Cancer Nursing Practice (2013) 12; 9: 33-38
  • Randomized Phase II Study of PEGylated SN-38 (EZN-2208) With or Without Cetuximab in Patients with Advanced Colorectal Cancer. Garrett CR, Bekaii-Saab TS, Ryan TF, Fisher GA, Clive S, Kavan P, Shacham-Shmueli E, Buchbinder A, Goldberg RM. Cancer (2013) Sep 16. doi: 10.1002/cncr.28358
  • A Phase I Pharmacokinetic Study of PM00104 (Zalypsis®) Administered as a 24-hour Intravenous Infusion Every Three Weeks in Patients with Advanced Solid Tumors. Capdevila J, Clive S, Casado E, Michie C, Piera A, Sicart E, Josep Carreras M, Coronado C, Kahatt C, Matos-Pita AS, Teruel CF, Siguero M, Cullell-Young M, Tabernero J. Cancer Chemother Pharmacol (2013) 71:1247–1254; DOI 10.1007/s00280-013-2119-8
  • Principles of dose finding studies in cancer: a comparison of trial designs. Jaki T, Clive S, Weir C. Cancer Chemother Pharmacol (2013) 71:1107–1114; DOI 10.1007/s00280-012-2059-8
  • Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients. Clive S, Woo M, Nydam T, Kelly L, Squier M, Kagan M. Cancer Chemotherapy and Pharmacology (2012); DOI: 10.1007/s00280-012-1940-9
  • Accuracy of GFR estimation by the Cockroft and Gault, MDRD and Wright equations in Oncology patients with renal impairment. Faluyi OO, Masinghe SP, Hayward RL, Clive S. Med Oncol (2012); 29 (2):755-60, DOI: 10.1007/s12032-011-9824-0           
  • The frequency and severity of capecitabine-induced hypertriglyceridaemia in routine clinical practice; a prospective study. Michie C, Clive S. British Journal of Cancer (2010); 103 (5):617-21
  • Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy? Storey DJ, Sakala M, McLean CM, Phillips HA, Dawson LK, Wall LR, Fallon MT, Clive S. Annals of Oncology (2010). 21(8):1657-1661
  • Capecitabine (oral 5-fluorouracil pro-drug) treatment for colorectal carcinoma causing ischaemic chest pain T McGoldrick, D Jodrell, S Clive. British Medical Journal (2009), Case Reports2009:; doi:10.1136/bcr.07.2008.0449
  • The value of adjuvant treatment in young women with breast cancer. Clive S, Dixon JM. Drugs (2002), 62(1), 1-11.
  • Forearm blood flow and local responses to peptide vasodilators: A novel pharmacodynamic measure in the phase I trial of Antagonist G, a neuropeptide growth factor antagonist. Clive S, Webb DJ, MacLellan J, Young A, Byrne B, Robson L, Smyth JF, Jodrell DI. Clinical Cancer Research (2001), 7, 3071-3078.
  • Gastrin-releasing peptide is a potent vasodilator in humans. Clive S, Jodrell D, Webb D. Clinical Pharmacology and Therapeutics (2001), 69(4), 252-9.
  • Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. Clive S, Gardiner J, Leonard RCF. Cancer Chemotherapy and Pharmacology (1999), 44, 7 (S29-S30).
  • Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients. Reigner B, Clive S, Cassidy J, Jodrell DI, Schulz R, Goggin T, Banken L, Roos B, Utoh M, Mulligan T, Weidekamm E. Cancer Chemotherapy and Pharmacology (1999), 43, 309-315.
  • A simple non-invasive method of assessing the acute haemodynamic effects of doxorubicin. Clive S, Dawson AA, Bennet NB, Rawles JM. Haematological Oncology (1991), 9, 1, 53-58.
  • Small Cell Ovarian Cancer - a rare aggressive tumour treated with high dose chemotherapy. Clive S, Smyth JFS. Oncology Today (1998), 18, 17-19.
  • Miltefosine in recurrent cutaneous breast cancer. Clive S, Leonard RCF. Lancet (1997), 349, 621-622.
  • Necrobacillosis (Lemmiere’s Syndrome): a rare cause of necrotising pneumonia. Dykhuizen RS, Olson JS, Clive S, Douglas JG. The European Respiratory Journal (1994), 7, 2246-2248.

Partners and Funders

  • NRS Career Researcher Award

 

This article was published on